163 related articles for article (PubMed ID: 23256748)
21. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
22. Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis.
Blankenberg FG; Levashova Z; Goris MG; Hamby CV; Backer MV; Backer JM
J Nucl Med; 2011 Oct; 52(10):1630-7. PubMed ID: 21890879
[TBL] [Abstract][Full Text] [Related]
23. Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist
Reidy-Lagunes D; Pandit-Taskar N; O'Donoghue JA; Krebs S; Staton KD; Lyashchenko SK; Lewis JS; Raj N; Gönen M; Lohrmann C; Bodei L; Weber WA
Clin Cancer Res; 2019 Dec; 25(23):6939-6947. PubMed ID: 31439583
[TBL] [Abstract][Full Text] [Related]
24. Enhancing Treatment Efficacy of
Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
[TBL] [Abstract][Full Text] [Related]
25. Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer.
Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Schmitt J; Forssel-Aronsson E
Cancer Biother Radiopharm; 2003 Aug; 18(4):593-9. PubMed ID: 14503955
[TBL] [Abstract][Full Text] [Related]
26. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
[TBL] [Abstract][Full Text] [Related]
27. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Wiseman GA; White CA; Sparks RB; Erwin WD; Podoloff DA; Lamonica D; Bartlett NL; Parker JA; Dunn WL; Spies SM; Belanger R; Witzig TE; Leigh BR
Crit Rev Oncol Hematol; 2001; 39(1-2):181-94. PubMed ID: 11418315
[TBL] [Abstract][Full Text] [Related]
28. Comparative biodistributions and dosimetry of [¹⁷⁷Lu]DOTA-anti-bcl-2-PNA-Tyr³-octreotate and [¹⁷⁷Lu]DOTA-Tyr³-octreotate in a mouse model of B-cell lymphoma/leukemia.
Balkin ER; Liu D; Jia F; Ruthengael VC; Shaffer SM; Miller WH; Lewis MR
Nucl Med Biol; 2014 Jan; 41(1):36-42. PubMed ID: 24267052
[TBL] [Abstract][Full Text] [Related]
29. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
[TBL] [Abstract][Full Text] [Related]
30. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
31. Voxel-Based Dosimetry of Iron Oxide Nanoparticle-Conjugated
Gupta A; Shin JH; Lee MS; Park JY; Kim K; Kim JH; Suh M; Park CR; Kim YJ; Song MG; Jeong JM; Lee DS; Lee YS; Lee JS
Mol Pharm; 2019 Apr; 16(4):1498-1506. PubMed ID: 30821463
[TBL] [Abstract][Full Text] [Related]
32. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.
Pan MH; Gao DW; Feng J; He J; Seo Y; Tedesco J; Wolodzko JG; Hasegawa BH; Franc BL
Mol Imaging Biol; 2009; 11(3):159-66. PubMed ID: 19034582
[TBL] [Abstract][Full Text] [Related]
33. Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma.
Yadav MP; Singla S; Thakral P; Ballal S; Bal C
Nucl Med Commun; 2016 Jul; 37(7):735-42. PubMed ID: 26974315
[TBL] [Abstract][Full Text] [Related]
34. Monte Carlo dosimetry of a realistic multicellular model of follicular lymphoma in a context of radioimmunotherapy.
Bordes J; Incerti S; Mora-Ramirez E; Tranel J; Rossi C; Bezombes C; Bordenave J; Bardiès M; Brown R; Bordage MC
Med Phys; 2020 Oct; 47(10):5222-5234. PubMed ID: 32623743
[TBL] [Abstract][Full Text] [Related]
35. Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy.
Jiang L; Miao Z; Kimura RH; Liu H; Cochran JR; Culter CS; Bao A; Li P; Cheng Z
Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):613-22. PubMed ID: 21153409
[TBL] [Abstract][Full Text] [Related]
36. Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
Yordanov AT; Hens M; Pegram C; Bigner DD; Zalutsky MR
Nucl Med Biol; 2007 Feb; 34(2):173-83. PubMed ID: 17307125
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals.
Müller C; Farkas R; Borgna F; Schmid RM; Benešová M; Schibli R
Bioconjug Chem; 2017 Sep; 28(9):2372-2383. PubMed ID: 28898054
[TBL] [Abstract][Full Text] [Related]
38. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
Wiseman GA; White CA; Stabin M; Dunn WL; Erwin W; Dahlbom M; Raubitschek A; Karvelis K; Schultheiss T; Witzig TE; Belanger R; Spies S; Silverman DH; Berlfein JR; Ding E; Grillo-López AJ
Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488
[TBL] [Abstract][Full Text] [Related]
39. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
[TBL] [Abstract][Full Text] [Related]
40. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
